Apr. 24 at 3:07 PM
$SPRB — one of the cleanest asymmetric small-cap biotech setups on my radar right now.
👉Click to view @NasdaqPulse for timely updates amid the volatility.
They just locked in a ~
$60M raise, which removes near-term funding risk and gives them a full runway into multiple catalysts over the next 12 months. That alone resets the downside profile.
Meanwhile, market cap still sitting around ~
$140M… that disconnect is exactly where traders get paid.
You’ve got high-profile eyes like Martin Shkreli calling for extreme upside (even after dilution), but even stripping that out — a more grounded scenario still points to multi-bagger potential if execution lands.
Low float + fresh capital + upcoming data = volatility expansion setup.
And don’t ignore the M&A angle — this is the type of beaten-down, recapitalized biotech that gets scooped when sentiment flips.
Not chasing — but definitely stalking this one into catalysts. Risk/reward skew is hard to ignore.
